tru Independence’s Windtree Therapeutics WINT Stock Holding History

tru Independence’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	-$308	–	714
2020 Q4	$308	Buy	+1	New	+$277K	﹤0.01%	406

Other funds holding WINT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

tru Independence's WINT Position: Q1 2021 in Review

tru Independence sold out of Windtree Therapeutics (WINT) in Q1 2021, closing a stake of 1 share — an estimated $308 sold.

tru Independence first reported a position in WINT in Q4 2020 and held it in 1 quarter. The position peaked at $308 in Q4 2020. 9 funds tracked by Wall St. Rank hold WINT as of Q1 2021.

tru Independence reported no remaining Windtree Therapeutics position as of Q1 2021 after selling out during the quarter.
tru Independence sold 1 Windtree Therapeutics share in Q1 2021, an estimated $308.
tru Independence first reported a position in Windtree Therapeutics in Q4 2020 and held it in 1 quarter.
tru Independence's Windtree Therapeutics position peaked at $308 in Q4 2020.
9 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2021.

Based on tru Independence's 13F filing for Q1 2021, filed 20 May 2021.